Merck & Co. Inc., of Whitehouse Station, N.J., is collaborating with Glaxosmithkline plc, of London, to test Merck’s anti-PD-1 immunotherapy, MK-3475, with GSK’s oral kinase inhibitor, pazopanib, in advanced renal cell carcinoma. The companies began a Phase I/II trial evaluating safety and efficacy of the compound in treatment-naïve patients with the disease. Under the collaboration, the companies will study MK-3475 with pazopanib and other agents in the GSK portfolio in the future.